U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509749) titled 'Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)' on Jan. 05.
Brief Summary: The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )
Study Start Date: June 30, 2025
Study Type: INTERVENTIONAL
Condition:
GVHD, Acute
Stem Cell Transplant Complications
Intervention:
DRUG: Ruxolitinib and Methylprednisolone
Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone (1mg/kg)
DRUG: Methylprednisolone
Methylprednisolone 2mg/kg/d , iv or iv gtt for at least 1 ...